Introduction to Multiple Mitochondrial Dysfunctions Syndrome 1

Multiple mitochondrial dysfunctions syndrome 1 (MMDS1) represents a rare and severe autosomal recessive metabolic disorder. It primarily arises from defects in the NFU1 gene, which encodes a critical iron-sulfur cluster (ISC) scaffold protein. Consequently, this genetic impairment disrupts the maturation of essential mitochondrial proteins. Clinicians often identify this condition during infancy due to its rapid and progressive clinical course. Understanding the underlying molecular mechanisms is vital for early diagnosis and potential intervention.

Clinical Presentation of Multiple Mitochondrial Dysfunctions Syndrome 1

Patients with this disorder typically present with a triad of infantile-onset lactic acidosis, hyperglycinemia, and pulmonary arterial hypertension (PAH). Furthermore, neurological manifestations such as refractory epilepsy, encephalopathy, and severe hypotonia frequently complicate the clinical picture. However, the presence of PAH remains one of the most distinctive features of MMDS1 compared to other mitochondrial syndromes. This cardiovascular involvement often dictates the prognosis and requires aggressive hemodynamic management. Recent case reviews suggest that the previously noted sex-based differences in animal models do not appear to manifest in human patients.

Pathophysiology and Genetic Mechanisms

The NFU1 protein plays a mandatory role in trafficking iron-sulfur clusters to recipient proteins like lipoate synthase and respiratory chain complexes. Additionally, defects in this pathway lead to a global dysregulation of energy metabolism and excessive production of reactive oxygen species (ROS). Notably, the Gly208Cys variant is the most common pathogenic mutation identified in human cases. This specific mutation impairs the transfer of clusters to target proteins, effectively starving the mitochondria of functional enzymes needed for oxidative phosphorylation. Therefore, the cellular impact extends far beyond simple energy deficiency, involving complex oxidative stress pathways.

Diagnostic Strategies and Therapeutic Insights

Early identification of MMDS1 relies on recognizing the unique combination of metabolic and pulmonary symptoms. Specifically, clinicians should maintain a high index of suspicion when encountering an infant with unexplained lactic acidosis and PAH. Rapid genome sequencing (GS) has emerged as the gold standard for confirming compound heterozygous or homozygous variants in the NFU1 gene. While definitive cures currently do not exist, identifying these cellular defects provides a foundation for future therapeutic research. Supportive care remains the cornerstone of management, focusing on seizure control and stabilizing respiratory function.

Frequently Asked Questions

What is the primary cause of MMDS1?

MMDS1 is caused by mutations in the NFU1 gene, which is responsible for the maturation and transport of iron-sulfur clusters within the mitochondria.

Why is pulmonary arterial hypertension common in MMDS1?

While the exact mechanism is still being studied, it is linked to the dysregulation of energy metabolism and increased oxidative stress in the pulmonary vasculature due to ISC pathway defects.

How is this condition diagnosed in infants?

Diagnosis is usually achieved through clinical observation of lactic acidosis and PAH, followed by confirmation using rapid genome sequencing to identify NFU1 variants.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

DiFalco CR et al. A Case of Multiple Mitochondrial Dysfunctions Syndrome 1 and Review of the Literature. Am J Med Genet A. 2026 May 26. doi: 10.1002/ajmg.a.70213. PMID: 42192213.

Lebigot E et al. A Review of Multiple Mitochondrial Dysfunction Syndromes, Syndromes Associated with Defective Fe-S Protein Maturation. Frontiers in Genetics. 2021.

Kropp PA et al. Patient-specific variants of NFU1/NFU-1 disrupt cholinergic signaling in a model of multiple mitochondrial dysfunctions syndrome 1. Disease Models & Mechanisms. 2023.